More than half of US adults ages 30 to 79 are now recommended for statin therapy under updated cholesterol management guidelines, according to a University of Pittsburgh study published in JAMA.
The analysis found that expanded recommendations increase the number of adults eligible for cholesterol-lowering medication by 21.5 million, bringing the total to approximately 87.5 million people.
The findings highlight how changes in cardiovascular risk assessment may influence the use and interpretation of laboratory measurements, including lipid panels used to support treatment decisions.
Timothy Anderson, MD, MAS, a primary care physician at UPMC and health services researcher and assistant professor of medicine at the University of Pittsburgh.
UPMC/John Dillard
A shift toward longer-term cardiovascular risk
In March 2026, the American Heart Association, American College of Cardiology, and other organizations released updated guidelines for managing high cholesterol. The recommendations incorporated an updated risk calculator and expanded the age range for assessment from 40–75 years to 30–79 years.
The updated guidelines also extend the risk horizon from 10 years to 30 years, emphasizing the cumulative effects of cholesterol exposure over a person’s lifetime.
“The shift to a longer view of cardiovascular disease risk is a sea change for doctors in counseling patients,” said Timothy S. Anderson, MD, MAS, a primary care physician, health quality researcher, and assistant professor of medicine at the University of Pittsburgh. “We wanted to better understand the potential population-health effect of this shift.”
Researchers analyzed data from 4,366 participants in the National Health and Nutrition Examination Survey, representing approximately 154.5 million US adults without existing cardiovascular disease from 2017 to 2023. The study focused on primary prevention and excluded pregnant individuals.
Expanded eligibility may increase lipid testing needs
Statin eligibility increased most among adults who have low short-term cardiovascular risk but higher estimated risk over several decades. While only 11.1% of adults in their 30s met eligibility criteria, eligibility increased to 85% among adults in their 60s and 93.5% among those in their 70s.
The authors noted that the increase was largely driven by people considered low risk over 10 years but with a higher projected risk over 30 years. This longer-term approach may change how clinicians use cholesterol measurements when discussing preventive treatment options.
“Many of my younger patients wonder why they can’t put off starting treatment—which is understandable, given they might have low risk of a cardiovascular event 10 years out—and some likely can with a strong focus on healthy diet, exercise and weight,” Anderson said. “But for patients seeking to fully minimize risks of heart attacks and strokes, early statin therapy may be a good choice.”
Anderson emphasized that medication decisions remain individualized and should consider potential cardiovascular benefits, adverse drug events, costs, and patient preferences. Lifestyle interventions, including healthy diet, exercise, and smoking cessation, remain central to cardiovascular disease prevention.
“Ultimately, in this grey zone, patients should talk to doctors,” Anderson said. “This is a preference-based decision that should take into account the potential for modest cardiovascular risk reduction alongside the potential for adverse drug events, costs, and patient preferences.”
Note: This news summary was generated by AI based on a published press release, followed by a review from human editors.
